Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
PODCAST | Politics, Policy & Law

BIO’s Trump 2.0 plan. Plus: Autoimmune CAR Ts & Telix’s radiopharma play — a BioCentury podcast

Trade group CEO John Crowley hopes that by engaging with President Trump he can help protect and improve FDA

By Jeff Cranmer, Executive Editor
March 18, 2025 12:58 AM UTC

BIO is engaging with President Donald Trump to protect and improve FDA. It’s also hoping biopharmas can dodge tariffs and find paths to modify the Inflation Reduction Act and reinstate pediatric priority review vouchers. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin delivers takeaways from his conversation with John Crowley, CEO of the industry trade group.

BioCentury’s editors also discuss how autoimmune CAR T companies are competing for resources and the end-to-end radiopharma ambitions of Telix Pharmaceuticals Ltd. (ASX:TLX; NASDAQ:TLX). A 2023 landscape on the radiopharma space can be found here.

For BioCentury’s complete coverage of how biotech can navigate Trump 2.0, see the Hot Topics page. 

Purchase Reprint/Distribution Rights
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Telix Pharmaceuticals Ltd.

U.S. Food and Drug Administration (FDA)